Crescent Biopharma
CBIO
78 hedge funds and large institutions have $220M invested in Crescent Biopharma in 2019 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 21 increasing their positions, 27 reducing their positions, and 14 closing their positions.
90% more call options, than puts
Call options by funds: $74K | Put options by funds: $39K
22% more capital invested
Capital invested by funds: $180M → $220M (+$40.3M)
21% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 14
4% more funds holding
Funds holding: 75 → 78 (+3)
0.01% less ownership
Funds ownership: 0.96% → 0.96% (-0.01%)
22% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 27
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$1.51M |
| 2 |
Morgan Stanley
New York
|
+$1.43M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$746K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$720K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$640K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$3.54M |
| 2 |
Millennium Management
New York
|
-$829K |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$819K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$717K |
| 5 |
BlackRock
New York
|
-$549K |
CBIO Hedge Fund Activity: Q4 2019 in Review
78 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q4 2019, worth a combined $220M — up 22% from $180M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new CBIO positions and 14 closed out — a net gain of 3 holders — while 21 added to existing stakes and 27 trimmed.
The largest buyer was Arrowstreet Capital, opening a new position worth an estimated $1.51M. The largest seller was Redmile Group, cutting an estimated $3.54M.
- 78 institutional investors held Crescent Biopharma (CBIO) as of Q4 2019, up from 75 in Q3 2019.
- Funds reported $220M of Crescent Biopharma stock for Q4 2019, up 22% quarter-over-quarter.
- 17 funds opened new Crescent Biopharma positions in Q4 2019 and 14 closed out, a net change of +3 holders.
- The largest Crescent Biopharma buyer in Q4 2019 was Arrowstreet Capital, an estimated $1.51M added.
- The largest Crescent Biopharma seller in Q4 2019 was Redmile Group, an estimated $3.54M sold.
Based on aggregated 13F filings for Q4 2019.